Plasma trimethylamine N-oxide concentration and all-cause mortality in kidney transplant recipients
Nephrology Dialysis Transplantation · 2025
DOI: 10.1093/ndt/gfaf071 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Manuela Yepes-Calderón und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Biomarkers, Kidney Failure, Chronic, Kidney Transplantation, Methylamines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Astellas BV, Chiesi Pharmaceuticals BV, NWO.
Abstract (Originalsprache)
Background and hypothesis Trimethylamine N-oxide (TMAO) is a pro-atherosclerotic molecule produced by intestinal microbiome. TMAO has been linked to increased mortality risk in chronic kidney disease, but its effect in kidney transplant recipients (KTR) is unclear. We investigated the pre–post-transplantation plasma TMAO change, and the association of post-transplantation plasma TMAO with all-cause mortality in KTR.
Methods
This prospective study included two cohorts. Cohort A comprised 623 KTR from the TransplantLines Cohort and Biobank Study (ClinicalTrials.gov: NCT03272841), and assessed pre-transplantation and at 3, 6, 12 and 24 months post-transplantation. Cohort B included 544 KTR with a functioning graft for ≥1 year [median 7.4 (3.9–13.0) years post-transplantation] to study late associations. Potential kidney donors (n = 315) served as healthy controls. Plasma TMAO was measured by proton nuclear magnetic resonance. Time-dependent coefficient Cox regression analyses were performed to assess TMAO association with all-cause mortality.
Results
Plasma TMAO concentration significantly declined after transplantation {from 29.0 [interquartile range (IQR) 20.6–48.5] µmol/L to 4.5 (IQR 2.7–8.6) mol/L at 3-months post-transplantation, P < .001}. Afterwards it remained stable [β –0.4 (95% confidence interval –2.2 to 1.34) µmol/L per post-transplantation year, P = .63], remaining consistently higher than that of healthy control [2.6 (IQR 1.8–4.3) µmol/L]. In Cohort A, during a median follow-up of 2.2 years, 41 KTR (7%) died. In Cohort B, over a median follow-up of 4.1 years, 78 KTR (14%) died. A 1-SD higher plasma TMAO concentration was independently associated with an increased risk of all-cause mortality in both cohorts [hazard ratio (95% confidence interval) 1.35 (1.19‒1.53); P < .001, and 1.34 (1.23‒1.47); P < .001; respectively].
Conclusion
Plasma TMAO decreases sharply after kidney transplantation, without reaching healthy controls levels. A higher plasma TMAO concentration was independently associated with an increased mortality risk in KTR. Further research is warranted to assess whether accounting for gut dysbiosis and TMAO could improve clinical outcomes in KTR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico.
- Labcorp, Diagnostics Research & Development, Morrisville, NC, USA.
- Division of Endocrinology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
ORCID-Profile: Manuela Yepes-Calderón, Daan Kremer, Tim J Knobbe, Martin H de Borst
Förderung
- Astellas BV
- Chiesi Pharmaceuticals BV
- NWO
- Dutch Ministry of Economic Affairs and Climate Policy
Zitieren
APA
Yepes-Calderón, M., Martín Del Campo Sanchez, F., Kremer, D., Knobbe, T. J., Gomes Neto, A. W., Connelley, M. A., Dullaart, R. P. F., Corpeleijn, E., de Borst, M. H., Bakker, S. J. L., & TransplantLines Investigators (2025). Plasma trimethylamine N-oxide concentration and all-cause mortality in kidney transplant recipients. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf071
Vancouver
Yepes-Calderón M, Martín Del Campo Sanchez F, Kremer D, Knobbe TJ, Gomes Neto AW, Connelley MA, et al. Plasma trimethylamine N-oxide concentration and all-cause mortality in kidney transplant recipients. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfaf071
BibTeX
@article{YepesCaldern2025,
author = {Yepes-Calderón, Manuela and Martín Del Campo Sanchez, Fernando and Kremer, Daan and Knobbe, Tim J and Gomes Neto, Antonio W and Connelley, Margery A and Dullaart, Robin P F and Corpeleijn, Eva and de Borst, Martin H and Bakker, Stephan J L and TransplantLines Investigators, TransplantLines Investigators},
title = {Plasma trimethylamine N-oxide concentration and all-cause mortality in kidney transplant recipients},
journal = {Nephrology Dialysis Transplantation},
year = {2025},
doi = {10.1093/ndt/gfaf071}
}
EUVIMED